No Data
No Data
Express News | Rockwell Medical Promotes Tim Chole to Chief Commercial Officer
HC Wainwright & Co. Reiterates Buy on Rockwell Medical, Maintains $9 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:RMTI) with a Buy and maintains $9 price target.
Rockwell Medical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 405.62% HC Wainwright & Co. → $9 Reiterates Buy → Buy 03/25/2024 405.62% HC Wainwright & Co. $1
Rockwell Medical: Strong Financial Performance and Strategic Partnerships Justify Buy Rating
Rockwell Medical Inc (RMTI) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and ...
Q1 2024 Rockwell Medical Inc Earnings Call